Association of Troponin T measurements with long-term outcomes in patients with coronary artery disease participating in a secondary prevention trial

Table 2 Secondary preventive target achievement for cardiovascular risk factors and medication use in patients with and without elevated cardiac Troponin T (< 14 ng/L) one year after myocardial infarction/percutaneous coronary intervention/coronary artery bypass grafting

Target achievement, (%)^a	Missing values	Elevated cardiac Troponin T	Low cardiac Troponin T	p
Target achievement, (%)^a	n = 1278	n = 241	n = 1037
Non-smoking	6 (0)	208 (86)	825 (80)	0.02
Blood pressure	3 (0)	131 (54)	621 (60)	0.11
LDL-cholesterol	36 (3)	186 (77)	722 (72)	0.11
HbA1c (if diabetes, n = 195)	10 (5)	26 (41)	70 (57)	0.04
Body mass index	90 (7)	49 (22)	235 (24)	0.48
Lipid lowering therapy	18 (1)	229 (96)	972 (95)	0.69
Acetylsalicylic acid	7 (1)	216 (90)	991 (96)	< 0.001
Physical activity	0 (0)	130 (54)	621 (60)	0.09

^anon-smoking, blood pressure < 140/90 mmHg, LDL-cholesterol < 2.5 mmol/l (2007–2017)/ < 1.8 mmol/l (2018–20,200)/ < 1.4 mmol/l (2021-), HbA1c < 53 mmol/l (7%), body mass index < 25 kg/m2, daily use of lipid lowering therapy, daily use of acetylsalicylic acid, physical activity of minimum moderate intensity ≥ 150 min weekly

ISSN: 1471-2261